thinking is correct and positive.
However, they are not targeting any blockbusters and cannot launch to market at a pace that covers cash burn which was A$3.5mil at half (including a R&D rebate of A$2.0mil), expect cash to be under A$10.mil at the FY.
If you do the math on ELMA the market was USD39.mil per announcement on submission of dossier (5 competitors) it is know USD22.0mil at end of March 20, this will be new entrants/price cutting. Acrux and Harris will further reduce the market with their grab for share, even if profit share is 50:50 Acrux-Harris I would expect contribution to be under USD1.0mil pa.
Ann: Acrux Signs Licensing Agreement with Harris Pharmaceutical, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
-0.002(11.1%) |
Mkt cap ! $6.548M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.0¢ | 1.6¢ | $39.34K | 2.216M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 971151 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 565000 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| ACR (ASX) Chart |